Low testosterone—clinically termed hypogonadism—refers to inadequate production of testosterone by the testes (primary hypogonadism) or insufficient stimulation by the hypothalamus and pituitary (secondary hypogonadism). Testosterone is central to sexual development and maintenance, but it also supports muscle mass and function, erythropoiesis, bone mineral density, insulin sensitivity, mood regulation, and aspects of cognition. When androgen levels fall below physiologic needs, patients may experience a constellation of symptoms that can mimic depression, chronic illness, or endocrine disorders.
Physiology and pathophysiology begin with the hypothalamic–pituitary–gonadal axis. The hypothalamus secretes GnRH in pulses, stimulating pituitary LH (luteinizing hormone) and FSH (follicle-stimulating hormone). LH drives Leydig cell testosterone synthesis, while FSH supports Sertoli cell function and spermatogenesis. In primary hypogonadism, testosterone production is impaired, leading to high LH/FSH with low testosterone. In secondary hypogonadism, LH/FSH are low or inappropriately normal, reflecting reduced GnRH or pituitary output. Testosterone deficiency can also result from medication effects (e.g., opioids, glucocorticoids), systemic illness, obesity-associated suppression of gonadotropins, iron overload, testicular injury, and genetic conditions such as Klinefelter syndrome.
Common clinical features include reduced libido, erectile dysfunction, decreased morning erections, infertility or reduced semen volume, gynecomastia, fatigue, and diminished physical performance. Many men also report depressive symptoms, irritability, reduced motivation, and impaired concentration. Body composition changes are frequent: increased visceral fat and reduced lean mass. Skeletal effects include decreased bone mineral density, raising fracture risk over time. In younger patients, delayed puberty or absent secondary sexual characteristics may be the initial presentation.
Diagnosis requires careful biochemical confirmation and correlation with symptoms. A total testosterone level is typically measured in the morning (often between 7–10 a.m.) because of diurnal variation. Because testosterone fluctuates, guidelines generally recommend repeating the measurement on a separate day when results are borderline or low. Interpreting results is more complex in the setting of altered sex hormone–binding globulin (SHBG), which can be affected by obesity, aging, liver disease, thyroid disorders, and certain medications. When total testosterone is equivocal, clinicians may use free testosterone or calculate it using SHBG and albumin. After confirming low testosterone, clinicians assess etiology using serum LH and FSH. Elevated LH/FSH suggests primary testicular failure; low/inappropriately normal gonadotropins suggests secondary hypogonadism.
Additional laboratory evaluation may include prolactin (to exclude hyperprolactinemia), thyroid function tests, iron studies in suspected hemochromatosis, and evaluation for pituitary or hypothalamic disease when secondary hypogonadism is suspected. If red flags are present—severe headaches, visual field defects, neurologic symptoms, or markedly low gonadotropins—pituitary imaging may be indicated. Assessing fertility goals is essential, since testosterone therapy can suppress spermatogenesis via negative feedback on gonadotropins.
Treatment depends on cause, symptom severity, and patient goals. Lifestyle measures can be important for modifiable contributors. Weight loss in obesity may improve endogenous testosterone and gonadotropin signaling. Addressing sleep apnea, minimizing opioid exposure when possible, and optimizing glycemic control can improve hormonal function.
For symptomatic men with confirmed hypogonadism, testosterone replacement therapy (TRT) is the cornerstone of androgen repletion. TRT is available as intramuscular injections, transdermal gels/patches, subcutaneous formulations, and other routes. Clinical response is tracked for libido, energy, mood, sexual function, and physical performance. Monitoring includes hematocrit (to detect TRT-associated erythrocytosis), prostate-specific antigen (PSA) and prostate evaluation based on age and risk, and periodic reassessment of testosterone levels to ensure therapeutic—but not excessive—ranges.
Safety considerations require attention to contraindications and adverse effects. TRT is generally avoided in men with known or suspected prostate cancer or high-risk prostate pathology, and it requires caution in those with severe untreated obstructive sleep apnea or uncontrolled heart failure. Cardiovascular risk has been debated; current evidence suggests that cardiovascular outcomes depend on patient selection and comorbidities rather than uniform harm, but clinicians should individualize treatment.
When fertility preservation is desired—particularly in secondary hypogonadism—alternative approaches may be preferred. Gonadotropin therapy (e.g., hCG, sometimes combined with FSH) can stimulate endogenous testosterone while supporting spermatogenesis. Selective estrogen receptor modulators or aromatase inhibitors may be used in selected cases under specialist care, aiming to increase gonadotropin drive. In hyperprolactinemia, treating the underlying cause or using dopamine agonists can restore the axis.
Low testosterone is therefore not merely a marker of aging; it is a treatable endocrine condition with specific diagnostic pathways and tailored management. Persistent symptoms warrant structured evaluation to determine etiology, confirm biochemical deficiency, and select therapies that address both hormonal needs and patient priorities, including sexual health, bone and muscle preservation, and fertility. Source: @_Healthyorg (May 31, 2026).
Healthy & Organic: What you should know about low testosterone.. #breaking
— @_Healthyorg May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
